STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

September 5, 2022

The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria.

Our Scientists at Omnix Medical have published a study demonstrating the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii.

Results point to OMN6 as a novel antimicrobial agent targeting the most troubling bacteria with a novel mechanism of action, positioning our technology as the potential SoC to treat life-threatening infections caused by MDR bacteria. READ STUDY PUBLISHED 5 September 2022.

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii Download

More To Explore

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6, a Novel Antimicrobial Peptide Targeting Acinetobacter

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

Contact Us

Reach US

A-2-Z - Digital Accessibility and Marketing

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.

Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).